ESMO OPEN Journal
Overview
publication venue for
- Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109). 10. 2025
- A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. 9. 2024
- Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. 5. 2020
- Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. 3. 2018
Research
category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 2059-7029
Electronic International Standard Serial Number (EISSN)
- 2059-7029
Other
journal abbreviation
- ESMO OPEN